Sabril's Approval With REMS No Surprise, But May Provide Marketing Advantage
This article was originally published in The Pink Sheet Daily
Executive Summary
Periodic vision testing and a restricted distribution program will be required for Lundbeck's spasticity agent.
You may also be interested in...
Specialty Pharmacies Could Be Selling Point If FDA Approves Tasimelteon
A Nov. 14 advisory committee gave near-unanimous support for Vanda’s sleep disorder drug on questions about its indication, endpoints, efficacy and safety.
FDA Grades Itself Highly In Reports On Safety Of Imported Products And Marketed Drugs
As Congressional markups of user fee bills looms, the agency describes actions it has taken to protect the international supply chain in its Global Engagement report; another report notes the REMS and drug safety studies it has mandated under its postmarket drug safety program.
The REMS Ramp Up: FDA Using New Safety Tools More Frequently In Year Two
FDA is using its new Risk Evaluation and Mitigation Strategy authorities much more frequently in the second year since the law took effect